Compare SoFi Technologies Inc (SOFI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoFi Technologies Inc vs TG Therapeutics Inc — how do they compare? SoFi Technologies Inc trades at $17.19 (market cap $21.82B), while TG Therapeutics Inc trades at $54.49 (market cap $8.26B). The key difference: SoFi Technologies Inc is far larger — about 2.6× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| SOFI | TGTX | |
|---|---|---|
Market Cap | $21.82B | $8.26B |
Sector | Financials | Health |
52-Week High | $32.21 | $59.06 |
52-Week Low | $15.15 | $26.39 |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOFI Technologies trades at $17.07, down 1.22% with a bearish technical signal. The company shows strong revenue growth, reaching $3.61B in 2025 with consistent earnings beats, though net income declined to $481M. Analyst consensus is mixed with a $22.43 price target, while recent news highlights upcoming Q2 earnings and takeover speculation.
SOFI presents growth potential with 30% revenue guidance and digital platform expansion, but faces risks from negative operating cash flow and competitive pressures. The stock's current valuation at 38.4 P/E requires continued execution to justify upside from current levels.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
